Perceptive Advisors LLC raised its stake in CytomX Therapeutics Inc (NASDAQ:CTMX) by 79.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,490,381 shares of the biotechnology company’s stock after buying an additional 1,100,000 shares during the quarter. CytomX Therapeutics makes up approximately 1.7% of Perceptive Advisors LLC’s investment portfolio, making the stock its 14th largest position. Perceptive Advisors LLC owned about 6.48% of CytomX Therapeutics worth $52,571,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently modified their holdings of the company. Macquarie Group Ltd. purchased a new stake in CytomX Therapeutics in the 3rd quarter valued at $107,000. Bank of Montreal Can purchased a new stake in CytomX Therapeutics in the 4th quarter valued at $124,000. Voya Investment Management LLC purchased a new stake in CytomX Therapeutics in the 2nd quarter valued at $203,000. Nationwide Fund Advisors grew its holdings in CytomX Therapeutics by 39.4% in the 2nd quarter. Nationwide Fund Advisors now owns 16,365 shares of the biotechnology company’s stock valued at $254,000 after buying an additional 4,622 shares in the last quarter. Finally, Virtus Fund Advisers LLC purchased a new stake in CytomX Therapeutics in the 4th quarter valued at $339,000. Institutional investors own 78.50% of the company’s stock.
In related news, Director Frederick W. Gluck sold 3,819 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $30.00, for a total transaction of $114,570.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sean A. Mccarthy sold 13,052 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $21.04, for a total value of $274,614.08. Following the transaction, the insider now owns 17,695 shares of the company’s stock, valued at $372,302.80. The disclosure for this sale can be found here. Insiders have sold a total of 132,626 shares of company stock valued at $3,709,830 over the last 90 days. 8.00% of the stock is currently owned by company insiders.
CytomX Therapeutics Inc (NASDAQ:CTMX) opened at $34.10 on Monday. CytomX Therapeutics Inc has a twelve month low of $12.51 and a twelve month high of $35.00.
COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/03/12/perceptive-advisors-llc-has-52-57-million-holdings-in-cytomx-therapeutics-inc-ctmx.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.